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PPARαs are nuclear receptors highly expressed in colon cells. They can be activated by the fibrates (clofibrate, ciprofibrate etc.) used
to treat hyperlipidemia. Since PPARα transcriptional activity can be negatively regulated by JNK, the inhibition of JNK activity
could increase the effectiveness of PPARα ligands. We analysed the effects of AS601245 (a JNK inhibitor) and clofibrate alone or
in association, on proliferation, apoptosis, differentiation and the gene expression profile of CaCo-2 human colon cancer cells.
Proliferation was inhibited in a dose-dependent way by clofibrate and AS601245. Combined treatment synergistically reduced
cell proliferation, cyclin D1 and PCNA expression and induced apoptosis and differentiation. Reduction of cell proliferation,
accompanied by the modulation of p21 expression was observed in HepG2 cells, also. Gene expression analysis revealed that
some genes were highly modulated by the combined treatment and 28 genes containing PPRE were up-regulated, while clofibrate
alone was ineffective. Moreover, STAT3 signalling was strongly reduced by combined treatment. After combined treatment, the
binding of PPARα to PPRE increased and paralleled with the expression of the PPAR coactivator MED1. Results demonstrate that
combined treatment increases the effectiveness of both compounds and suggest a positive interaction between PPARα ligands and
anti-inflammatory agents in humans.
1. Introduction
PPARs are ligand-activated transcription factors belonging
to the nuclear receptor superfamily. Three molecular forms
of PPAR have been identified, namely, PPARα, PPARβ/δ,
and PPARγ, and all involved in many different biological
processes [1]. PPARα is the predominant PPAR subtype
highly expressed in liver, heart, proximal tubules of kidney
cortex, skeletal muscle, intestinal mucosa, and in brown
adipose tissues that are metabolically very active [2].
Endogenous ligands with high specificity for PPARα are
long-chain unsaturated fatty acids and fatty acid derivatives
[3, 4]. Fibrates, which are hypolipidemic drugs used in
the treatment of hyperlipidemia, are among the group of
synthetic ligands, which are the most important agonists of
PPARα.
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Since PPARα is expressed in the digestive tract and
mainly localized in the intestinal mucosa in the small
intestine and in the colon, it has been proposed that a
physiological role of the receptor may be to sense the total
flux of dietary fatty acids in key tissues [5]. Colon epithelial
cells can be physiologically exposed not only to fatty acids
but also to hypolipidemic drugs such as fibrates, all PPARα
agonists. For this reason, there is particular interest to study
the effect of PPARα ligands in colon cancer cells.
Less is known about the role of PPARα in human tu-
mors. Generally, activation of this PPAR by agonists causes
inhibition of tumor cell growth [6, 7]. In contrast, in liver
murine cell models, Wy-14,643, clofibrate, ciprofibrate, and
DEHPwere inducers of c-fos, c-jun, junB egr-1, andNUP475
[8]. Indeed, PPARα has been widely employed in hepatocar-
cinogenesis protocols for rodents [9, 10]. However, in human
cell models, PPAR ligands downregulate oncogenes and
upregulate proapoptotic genes also [11, 12]. In particular, the
proapoptotic role of PPARα ligands has been outlined by a
recent review [13].
Beside ligand induction, PPARα activity can be regulated
by JNK and p38 mitogen-activated protein kinase (MAPK)
phosphorylation. The p38 MAPK phosphorylates the A/B
domain of PPARα and enhances its ligand-dependent tran-
scriptional activity [14]. On the contrary, the activation of
ERK-MAPK decreases PPARα activity [15]. By inhibiting
Rho A, a component of Rho family proteins, which regulate
the JNK and the p38 MAPK cascades, cerivastatin stimulates
PPARα transcriptional activity by reducing its phosphoryla-
tion [16].
AS601245[1,3-Benzothiazol-2-yl-(2-{[2-(3-pyridinyl)
ethyl]amino}-4-pyrimidinyl) acetonitrile; JNK inhibitor V]
has been selected as a potent and selective JNK inhibitor
with anti-inflammatory properties [17]. In the present
work, we intend to assess its effect on clofibrate action in
colon cancer cells. In particular, we examined the effects
of AS601245 and clofibrate, alone or in association, on
apoptosis, differentiation, and PPRE binding activity of
PPARα in CaCo-2 human colon cancer cells and analysed,
through microarray analysis (Affymetrix GeneChip), the
gene expression pattern in control and drug-treated cells.
Moreover, since the liver is the major target organ expressing
PPARα, to assess whether combined treatment could
produce some toxic effects in liver cells, we tested, through
MTT analysis, the acute toxicity of the both substances
and the effect of single and combined treatments on cell
proliferation and proliferation-related gene expressions in
HepG2 human hepatic cells.
2. Materials and Methods
2.1. Cell Culture and Treatments. CaCo-2 and HepG2 cells,
obtained from European Collection of Cell Cultures
(ECACC), were cultured at 37◦C in a humidified atmosphere
of 5% CO2-air. For all experiments, cells, from 1 to 10
passages, were used. Cells were grown in D-MEM medium
supplemented with 10% fetal bovine serum (HyClone, Italy),
2mM glutamine, 1% nonessential amino acids solution
and 1% antibiotic mixture (penicillin streptomycin) (Sigma,
Milano, Italy).
Treatments with clofibrate and AS601245[1,3-benzothi-
azol-2-yl-(2-{[2-(3-pyridinyl)ethyl]amino}-4-pyrimidinyl)
acetonitrile; JNK inhibitor V] (SPRI, Geneva, Switzerland)
were performed by suspending the drugs in DMSO. The
concentration of vehicle in culture did not exceed 1%.
Moreover, cultures, treated with 1% DMSO alone, were
performed to exclude the vehicle’s effects.
2.2. Cell Proliferation and Viability. CaCo-2 cell proliferation
was evaluated by using the kit “CellTiter-Glo Luminescent
Cell Viability Assay” (Promega, Milano, Italy). This highly
sensitive assay detects the luminescence released by the
metabolically active cells. Quantification of luminescence
was expressed as RLU (relative light unit). For the prolif-
eration experiments, treatments were performed by adding
the drugs (at different concentrations) to the CaCo-2 cells
seeded at about 4,000 cells/well in a 96-well plate. HepG2 cell
proliferation was analysed through theMTTmethod. Briefly,
1500 cells/well were seeded in 200 μL of serum-supplemented
media and the following day treated with the drugs. 20 μL
of 5mg/mL thiazolyl blue tetrazolium bromide (M2128-
SIGMA Aldrich) was subsequently added to the cells and
removed 2 hours later. 100 μL of DMSO was added to the
cells, and the absorbance was recorded at 570 nm through a
96 well plate ELISA reader. Viability was evaluated through
Trypan blue (T8154 SIGMA Aldrich) exclusion test.
2.3. Detection of Apoptosis. Apoptosis was evaluated, 24 and
48 hours after the treatments, by using a Kit Caspase-GLO
3/7 Assay (Promega,Milano, Italy) and confirmed by TUNEL
test. The Caspase-GLO 3/7 assay determines the amount
of caspase 3 and 7 cleavage of the luminogenic substrate
resulting in luciferase reaction and production of light. The
TUNEL method from Promega (Milano, Italy) consists of
the terminal deoxynucleotidyl transferase-mediated nick-
end labelling of FITC-conjugated deoxyuridine triphosphate.
Incorporated fluorescein was detected using a fluorescence
microscope (Leitz, Dialux 20, Oberkochen, Germany). The
number of apoptotic cells was determined by counting
the percentage of green fluorescence-positive cells. At least,
100 cells were counted for each experiment. CaCo-2 cells
treated with 10mM butyrate were used as positive control
of apoptosis.
2.4. Detection of Differentiated Cells. Differentiation was de-
termined by counting the dome formation in the control
or treated cells. Dome formation, which can be attributed
to ion and water transport across polarized epithelial cells
[18], was quantified in confluent CaCo-2 monolayers using
inverted light microscopy and expressed as the number of
domes per square centimetre. Domes were recognised as a
cohesive group of approximately 30 cells or more that were
in a different plane of view compared to cells attached to the
culture plate.
Preliminary experiments demonstrated that results ob-
tained by dome count were similar to those obtained
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with two other methods (transepithelial electrical resis-
tance (TEER) determination and phosphates alkaline assay)
(data not shown). CaCo-2 cells treated with 2mM sodium
butyrate (Sigma, Milano, Italy) were used as a positive
control.
2.5. RNA Extraction and Array Hybridization. Total RNA
from 3 biological replicates of each treatment was isolated
using TRIzol reagent (Invitrogen, Milano, Italy). Samples
were treated with DNase in order to avoid any genomic
contamination. The quality of the resulting RNA was
determined by using the Agilent 2100 Bioanalyzer (Agilent
Technologies), and RNA content was normalized by using
the Thermo Scientific NanoDropND-1000 spectrophotome-
ter. RNA samples of each replicate were analyzed by using
Affymetrix GeneChip Human Genome U133A plus 2.0 chips
(Affymetrix).
GCOS software version 1.2 (Affymetrix) was used to
define the probe cell and to calculate the intensity for each
cell. CEL files generated were analyzed for the overall data
quality using R/Bioconductor. Then, they were processed
into the Rosetta Resolver dataset for data normalization,
generation of expression values, and statistical analysis.
Expression values of all treatment groups were obtained as
a ratio versus the negative control (1% DMSO).
Differential analyses between pairs of groups were per-
formed with 1-way ANOVA followed by the Benjamini-
Hochberg multiple testing correction (False Discovery Rate-
FDR cut-off of 1%) and a Student-Newman-Keuls post
hoc analysis. Finally, differentially expressed genes were
analysed in Ingenuity Pathway Analysis software version 7.5
(Ingenuity Systems, http://www.ingenuity.com/).
2.6. Real-Time RT-PCR. We selected 4 genes that had
shown an approximately 2-fold change in expression for
further study by RT-PCR in a separate experiment. Two of
these (GANAB and IL6ST) were found to be increased in
Affymetrix analysis, whereas the other two were found to
be decreased (FGFR2 and CCNG). Total RNA was reverse
transcribed into cDNA in a 20 μL reaction using the
TaqMan High Capacity cDNA Reverse Transcription Kit
provided by Applied Biosystems. 500 ng of total RNA
was used as the starting material from each sample. For
each Real-Time PCR reaction, the reverse transcribed sam-
ple was used as a template. Target mRNA was quan-
tified using an ABI 7900 HT Fast real-time PCR sys-
tem (Applied Biosystems). Primers were purchased from
Applied Biosystems: GANAB (glucosidase, alpha; neutral
AB, Hs00929274 m1), IL6ST (interleukin 6 signal trans-
ducer (gp130, oncostatin M receptor, Hs00174360 m1),
CCNG (cyclin G2, Hs00171119 m1), and FGFR2 (fibroblast
growth factor receptor 2, Hs01552926 m1). The TaqMan
probes were labelled with a 5′ reporter dye (FAM, 6-
carboxyfluorescein) and a 3′ quencher dye (TAMRA, 6-car-
boxytetramethylrhodamine). Real-time PCR reactions were
carried out in triplicate. Data were analyzed by the ABI
Sequence Detection System (SDS) software using the relative
quantification. The fold changes are determined by the
ΔΔCt method as described in Applied Biosystems User
Bulletin no. 2.
2.7. DNA-Binding Activity of PPARα. The PPARα binding
activity assay was performed by using Trans-AM ELISA-
based kit from Active Motif (Carlsbad, CA, USA) according
to the manufacturer’s protocol. Briefly, cell extracts were
incubated in a 96-well plate coated with an oligonucleotide
containing the PPRE motif (5′-AACTAGGTCAAAGGTCA-
3′). PPAR contained in nuclear extract, specifically bound
to the immobilized oligonucleotide, was detected by using
an antibody anti-PPARα (clone H-98, from Santa Cruz
Biotechnology) followed by a secondary HRP- (horseradish-
peroxidase-) conjugated antibody (Bio-Rad Laboratories) in
an ELISA-like assay.
2.8. Western Blot Analysis. Total extracts were prepared by
lysis in a buffer containing Tris-HCl buffer, pH 7.4, 150mM
NaCl, 5mM EDTA, 1% Nonidet P-40, 1mM sodium
orthovanadate, 1mM phenylmethylsulfonyl fluoride, and
0.05% aprotinin. Insoluble proteins were discarded by high-
speed centrifugation at 4◦C. Protein concentration in the
supernatant was measured in triplicate using a commercially
available assay (Bio-Rad Laboratories, Segrate, Italy).
All proteins were separated by SDS-polyacrylamide
gel and electroblotted on nitrocellulose membrane (Bio-
Rad Laboratories, Segrate, Italy). Membranes were blocked
overnight at 4◦C in Tris buffered saline (TBS) containing
5% milk plus 0.5% Tween 20 and then incubated at room
temperature with primary antibodies (anti-P-PPAR alpha
(Ser21) from Thermo Scientific; anti-PPAR alpha from
Millipore; anti-STAT3 clone F-2, anti-p-STAT3 (Tyr705)
clone B-7, anti-PCNA clone FL-261, anticyclin D1 clone
A12 from Santa Cruz Biotechnology; anti-p-STAT3 (Ser727)
from ThermoScientific; anti-PPARBP (MED1) clone 2A2;
anti-β-actin clone AC-1 from Sigma-Aldrich; anti-P-Jun
from cell signaling; anti-p21 from Abcam and horseradish-
peroxidase-conjugated secondary antibodies (Bio-Rad Lab-
oratories, Segrate, Italy). Detection was carried out by
enhanced chemiluminescence (ECL) according to the man-
ufacturer’s protocol (Amersham-Pharmacia Biotech, Italy,
Cologno Monzese, Italy).
Densitometric analysis was performed by using a soft-
ware program (Multi-Analyst, version 1.1, Bio-Rad Labora-
tories, Segrate, Italy). All results were standardized using the
signal obtained with β-actin.
2.9. Statistical Analysis. The 2-way ANOVA was performed
in the proliferation, apoptosis, differentiation, and PPRE
binding assays.
3. Results
3.1. Growth of Clofibrate and AS601245-Treated Cells. Both
clofibrate and AS601245 were able to inhibit CaCo-2 cell
proliferation in a dose-dependent way (Figures 1(a) and
1(b)). To evaluate the efficacy on cell growth of the com-
bination of clofibrate and AS601245, we chose doses able
4 PPAR Research
to reduce cell proliferation by 20% (IC20) after 48 hours
of treatment. These doses were 5 μM clofibrate (IC 20 : 5 ±
0.4) and 0.1 μM AS601245 (IC 20 : 0.1 ± 0.01). Combined
treatment significantly reduced cell growth after 72 and 96
hours from the treatment (Figure 1(c)). The treatment with
two compounds synergistically reduced the cell growth after
72 hours, whereas, after 96 hours, the reduction is less
pronounced. The doses of 5 μMclofibrate, 0.1 μMAS601245,
and the combined treatment with these doses were used for
all the subsequent experiments.
3.2. Proliferation-Related Genes Expressions. Since the reduc-
tion of proliferation can be accompanied by the modu-
lation of specific genes, we determined the expression of
proliferating cell nuclear antigen (PCNA), cyclin D1 and
p21, in CaCo-2 cells. Moreover, we found that AS601245
at the concentration of 0.1 μM was able to inhibit Jun
phosphorylation in CaCo-2 cells. In Figure 2(a), the analysis
of P-Jun expression revealed that the amount of P-Jun
protein was reduced in cells treated with 0.1 μM AS601245.
A similar result was observed in cells treated with AS601245
plus clofibrate.
The PCNA expression was reduced in CaCo-2 cells only
after 72 hours from the treatments with clofibrate, AS601245,
and their combination (Figure 2(b)). Cyclin D1 expression
was induced by clofibrate 48 hours from the treatment, but,
in the following hours, its expression decreased particularly
in combined treatment (Figure 2(c)). Finally, p21 expression
did not vary significantly after the treatments (Figure 2(d)).
3.3. Apoptosis and Differentiation after AS601245 and
Clofibrate Treatments. Apoptosis detection is reported in
Figure 3. Both clofibrate and AS601245 were unable to
induce apoptosis when added separately to CaCo-2 cells.
Conversely, the association of these two compounds induced
a significant increase in caspase 3/7 activity, at 24 and 48
hours after the combined treatments. After 48 hours from
the combined treatment, the caspase 3/7 activity was about
4-fold higher than that detected in the control cells. These
results were confirmed by using TUNEL test (data not
shown).
Differentiation of CaCo-2 cells was induced by 0.1 μM
AS601245 at 48 hours after the treatment, whereas clofibrate
alone did not increase the Dome number (Figure 4). Com-
bined treatment increased the Dome number after 24 hours
and caused a greater induction of differentiation compared
to single treatments, after 48 hours (an increase of about 5-
fold with respect to the control value).
3.4. Microarray Analysis of Gene Expression in CaCo-2 Cells.
To analyze whether the cell responses to the treatments with
5 μM clofibrate, 0.1 μM AS601245, or with both substances
were a consequence of a specific gene pathway modulation,
we performed microarray analysis by using the Affymetrix
GeneChip platform, 24 hours after the treatments. The
complete list of the genesmodulated by clofibrate, AS601245,
and by the combined treatment is reported in the sup-
plementary data (See Table A in Supplementary Material
available online at doi:10.1155/2012/269751). To confirm
results obtained by microarray analysis, real time-PCR of
4 selected genes (2 upregulated and 2 downregulated) was
performed. Results, reported in supplementary data (Table
B), indicated that the up or down fold changes obtained
by microarray analysis were similar to those obtained in
real-time PCR. Some discrepancies were found only for
FGFR2 and CCNG that did not change in clofibrate treated
cells, if evaluated by microarray analysis, whereas they were
decreased by about −1.5-fold, if analysed by real-time PCR.
The supplementary data (Table C) also indicates the genes
affected by clofibrate, by AS601245, and by the combined
treatment with clofibrate and AS601245, arranged with
respect to the relative biological functions and listed on the
basis of the P value. The genes mainly affected by clofibrate,
which modulated a limited group of genes, belonged to
the “cancer,” “cellular development,” and “gene expression”
groups. AS601245 modulated genes belonging to “cancer,”
“cell cycle,” “genetic disorders,” and “cell death” groups. The
combined treatments affected mainly genes belonging to
“cancer” and “genetic disorder” functions.
The Venn diagram (Figure 5) shows that clofibrate mod-
ulated 182 genes, AS601245 modulated 2855 genes, and
the combined treatments modulated 848 genes. Among the
genes affected by clofibrate alone or AS601245 alone, 161
were common in both of the two groups. The combined
treatment affected 108 genes which were present in both
the clofibrate and AS601245 groups and 260 genes which
were not affected by either clofibrate or AS601245 alone.
Among these 260 genes, 65 only were downregulated by the
combined treatment, whereas 195 genes were upregulated.
The top ten genes changed the most by the clofibrate
treatment, with respect to 1% DMSO treated cells, are
reported in Table 1. Clofibrate treatment (Table 1(a)) mainly
increased the expression of the GANAB gene (3.8-fold
change) which encodes glucosidase alpha, the ATF6B gene
which encoded a transcription factor belonging the unfolded
protein response (UPR) pathway during ER stress [19, 20],
and some genes, belonging to “cancer” function (DLST,
IL6ST, MEX3d). Among genes downregulated by clofibrate,
the major part belonged mainly to functional groups:
“cancer” (STIP1, HNRNPA1, VIL1, and CDH1) and “cellular
assembly and organization” (CLASP1 and MACF1).
The genes modulated by the treatments with AS601245
are indicated in Table 1(b). In this case, the gene most
upregulated was CYP1A1 (5.3 fold change). The other
genes upregulated belonged mainly to the “cancer” and cell
death functions (NFAT5, BMO2K, DLST, IL6ST, FAM76B,
and MGA). The downregulated genes belonged mainly to
the “cancer” biofunction (RPS27A, HNRNPA1, STIP1, and
TFDP1).
The top ten genes affected the most by the combined
treatment with clofibrate and AS601245 are reported in
Table 1(c). Among the genes upregulated by the combined
treatment, 6 were upregulated by treatments with the single
substances also. CYP1A1 was increased by 7.5-fold, whereas
AS601245 alone induced its expression by 5.3-fold. IL6ST
was induced by clofibrate (2.0 fold), by AS601245 (2.5-fold
change), and, more intensively, by the combined treatment
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Figure 1: Caco-2 cell proliferation. (a) Growth of Caco-2 cells treated with clofibrate at the indicated concentrations (from 1 to 50 μM) and
at different times; (b) growth of Caco-2 cells treated with AS601245 at the indicated concentrations (from 0,1 to 10 μM) and at different
times; (c) growth of Caco-2 cells treated with 5 μM clofibrate, 0,1 μM AS601245, and the association of these two compounds (Clofi +
AS601245). Cell proliferation was detected by measuring the luminescence released by the metabolically active cells. The values expressed in
RLU (relative light units) are the means ± SD of three separate experiments. Variance analysis: ∗P < 0.05, ∗∗P < 0.01 versus control.
(6.5-fold change). AP3D1 was increased (3.6-fold change) in
AS601245 treated cells and with an even greater increase (5.0-
fold change) in cells treated with both compounds.
NFAT5 and GANAB genes remained almost unchanged
in combined treatment. Finally, SMRCC1 gene expression
was increased in AS601245-treated cells by a 2.0-fold change
(Table B) and by a 3.1-fold change in cells treated with
both substances. The resting genes (WASF2, VAPB, THRA,
and BDP1) were not affected in cells treated with a single
compound, whereas they were highly increased in cells
treated with both substances. Among the downregulated
genes, four genes which were unaffected by single treatments
(TRUB1, NXT2, FGB, and ACTC1) reached the top ten
positions in the combined treatment.
Other genes downregulated with the combined treat-
ment were downregulated also, to a lesser extent, in clo-
fibrate- and AS601245-treated cells (MALAT1, LARP5, and
TFRC) or in only AS601245-treated cells (SLC39A14).
Finally, two genes were downregulated by a single treatment
with AS601245 more than by the combined treatment
(HNRNPA1 and RPS27A).
We postulated that the inhibition of JNK could increase
the affinity of activated PPARα for the PPRE sequences. For
this reason, we investigated, among the genes activated by
clofibrate, by AS601245, and by the combined treatment,
the genes having PPRE sequences by using the genomewide
library of high-confidence predicted PPAR target genes
as published by Lemay and collaborators [21] (Table 2).
It is noteworthy that, among the genes upregulated by
the clofibrate 24 hours after the treatment, none had the
PPRE putative sequence in the promoter, indicating that
the clofibrate, at this concentration, was not able to induce
PPARα binding to PPRE containing genes. After treatment
with AS601245 and clofibrate, the number of activated genes,
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Figure 2: Proliferation-related protein expressions. (a) Determination of 0.1 μM AS601245 effect in reducing P-Jun expression; (b) time
course of PCNA expression in CaCo-2 cells treated with 5 μM clofibrate, 0.1 μM AS601245, and the association of these two compounds
(Clofi + AS601245); (c) time course of cyclin D1 expression in CaCo-2 cells treated with 5 μM clofibrate, 0.1 μM AS601245, and the
association of these two compounds (Clofi + AS601245); (d) time course of p21 expression in CaCo-2 cells treated with 5 μM clofibrate,
0.1 μM AS601245, and the association of these two compounds (Clofi + AS601245). Graphics represent the relative quantification of protein
products performed by densitometric scanning. Data were normalized by using the β-actin signal, expressed as arbitrary densitometric units,
and are the mean ± SD of three separate experiments from three different preparations for each condition. Variance analysis: ∗P < 0.05,
∗∗P < 0.01 versus control.
containing PPRE sequences, greatly increased (28 genes were
upregulated).
3.4.1. Effect of Clofibrate and AS601245 Treatments on PPARα
Binding to PPRE and Med1 Expression. Since microarray
analysis indicated that clofibrate alone did not induce
expression of genes containing PPRE sequences, whereas the
treatment with AS601245 and clofibrate does, we examined,
through Elisa assay, the binding of nuclear protein extracts
from control cells and cells treated with clofibrate alone,
AS601245 alone, and combined treatment with clofibrate
and AS601245, to PPRE sequences. Figure 6(a), indicates that
5 μM clofibrate and 0.1 μM AS601245 alone did not increase
the PPRE binding, whereas the PPRE binding activity was
increased in cells treated with 50 μM clofibrate and, more
intensively, in cells treated with 5 μM clofibrate and 0.1 μM
AS601245. This increase in binding activity is not linked
to the variation of PPARα phosphorylation in serine 21,
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Figure 3: Induction of apoptosis. Induction of apoptosis in CaCo-
2 cells treated with 5 μM clofibrate, 0.1 μM AS601245, and the
association of these two compounds (Clofi + AS601245). Apoptosis
was evaluated at 0, 24, and 48 hours after the treatments, by
measuring caspase 3/7 activity. 20 mM butyrate was used as a
positive control. Results normalized to the respective control value
for each experimental time is the mean ± SD of three separate
experiments from three different preparations for each condition.
Variance analysis: ∗∗P < 0.01 versus control.
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Figure 4: Induction of differentiation. Differentiation of CaCo-
2 cells treated with 5 μM clofibrate, 0.1 μM AS601245, and the
association of these two compounds (Clofi + AS601245). Cell
differentiation was evaluated at 24 and 48 hours after the start
of treatments, by measuring dome formation. 2mM butyrate was
used as a positive control. Results, expressed as number of domes
per cm2, are the mean ± SD of three separate experiments from
three different preparations for each condition. Variance analysis:
∗P < 0.05, ∗∗P < 0.01 versus control; $$P < 0.01, versus clofibrate-
treated cells; #P < 0.05 versus AS601245-treated cells. The picture
represents a microscopic image of domes.
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Figure 5: Microarray analysis of gene expression. Venn diagram
derived from microarray analysis of gene expression in CaCo-2 cells
treated with 5 μM clofibrate, 0.1 μM AS601245, and the association
of these two compounds (Clofi + AS601245) at 24 hours. The
diagram shows the number of genes modulated by the treatments.
as demonstrated by the western blot analysis with an anti-
phospho-PPAR alpha antibody (data not shown). However,
microarray analysis revealed that the PPAR alpha activator,
MED1, was increased in combined treated cells, only. To
verify if this increase corresponded to an increase in MED1
protein, we analyzed, by Western Blot, the expression of
MED1. Results confirmed thatMED1 protein was doubled in
cells treated with both compounds (Figure 6(b)); moreover,
its concentration was increased in cells treated with 50 μM
clofibrate also. To assess whether the increase of MED1
expression was maintained in the following days in cells
exposed to combined treatment, we performed a time-course
analysis of MED1 expression. The results confirmed that the
increase of MED1 expression was evident until 72 hours
after combined treatment (Figure 6(c)). Among the genes,
bearing PPRE sequences in their promoter and activated 24
hours after combined treatment, cyclin D1 has been found.
We demonstrated that cyclin D1 expression was increased
24 hours after treatment with 50 μM clofibrate and 5 μM
clofibrate plus 0.1 μM AS601245. These variations of cyclin
D1 expression at 24 hours were similar to those observed for
MED1 expression. (Figure 6(d)).
3.5. Analysis of JAK/STAT Signalling. The most important
gene, modulated by combined treatment, was IL6ST (also
called gp130).
This protein is the receptor for IL-6 cytokine. The bind-
ing induces the dimerization of gp130 chains resulting
in activation of Janus kinases (JAKs). JAKs phosphorylate
gp130, leading to the activation and phosphorylation of the
STAT1 and STAT3 transcription factors [22, 23]. Although
both transcription factors can be involved in gp130 down-
stream signalling, it has been demonstrated that STAT3
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Table 1: Top ten genesb.
(a) Clofibrate
Gene ID Gene name Fold change
GANAB∗ Glucosidase, alpha; neutral AB +3.8
ATF6B Activating transcription factor 6 beta +2.8
SETD5 SET domain containing 5 +2.6
NFAT5 Nuclear factor of activated T cells 5, tonicity-responsive +2.5
DLST Dihydrolipoamide S-succinyltransferase (E2 component of 2-oxoglutarate complex) +2.3
IL6ST Interleukin 6 signal transducer (gp130, oncostatin M receptor) +2.1
HNRNPA0 Heterogeneous nuclear ribonucleoprotein A0 +2.0
MEX3D Mex-3 homolog D (C. elegans) +1.6
CTSZ Cathepsin Z +1.5
STIP 1 Stress-induced phosphoprotein 1 −3.1
CLASP 1 Cytoplasmic linker-associated protein 1 −3.1
MACF 1 Microtubule-actin cross-linking factor 1 −2.9
COPA Coatomer protein complex, subunit alpha −2.7
HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 −2.6
SPSB2 SplA/ryanodine receptor domain and SOCS box containing 2 −2.3
TSR1 TSR1, 20S rRNA accumulation, homolog (S. cerevisiae) −2.3
VIL1∗ Villin 1 −2.3
CDH1 Cadherin 1, type 1, E-cadherin (epithelial) −2.2
CRTAP Cartilage-associated protein −2.2
(b) AS601245
Gene ID Gene name Fold change
CYP1A1 Cytochrome P450, family 1, subfamily A, polypeptide 1 +5.3
AP3D1 Adaptor-related protein complex 3, delta 1 subunit +3.6
NFAT5 Nuclear factor of activated T cells 5, tonicity-responsive +3.1
BMP2K Bone morphogenetic protein 2 inducible kinase +2.9
DLST Dihydrolipoamide S-succinyltransferase (E2 component of 2-oxoglutarate complex) +2.8
IL6ST Interleukin 6 signal transducer (gp130, oncostatin M receptor) +2.8
FAM76B Family with sequence similarity 76, member B +2.4
MGA MAX gene associated +2.4
THRAP3 Thyroid hormone receptor-associated protein 3 +2.4
GANAB Glucosidase, alpha; neutral AB +2.3
RPS27A Ribosomal protein S27a −4.2
HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 −4.1
WDR33 WD repeat domain 33 −3.9
EPN1 Epsin 1 −3.7
KLC2 Kinesin light chain 2 −3.6
STIP1 Stress-induced phosphoprotein 1 −3.6
SEPT9 Septin 9 −3.4
TFDP1 Transcription factor Dp-1 −3.1
LAD1 Ladinin 1 −3.1
CABIN 1 Calcineurin-binding protein 1 −3.1
(c) Clofibrate + AS601245
Gene ID Gene name Fold change
CYP1A1 Cytochrome P450, family 1, subfamily A, polypeptide 1 +7.5
IL6ST Interleukin 6 signal transducer (gp130, oncostatin M receptor) +6.4
AP3D1 Adaptor-related protein complex 3, delta 1 subunit +5.1
WASF2 WAS protein family, member 2 +4.1
PPAR Research 9
(c) Continued.
Gene ID Gene name Fold change
VAPB VAMP- (vesicle-associated membrane-protein-)associated protein B and C +3.9
NFAT5∗ Nuclear factor of activated T cells 5, tonicity-responsive +3.8
THRA Thyroid hormone receptor, alpha (erythroblastic leukemia viral (v-erb-a) oncogene homolog, avian) +3.6
GANAB∗ Glucosidase, alpha; neutral AB +3.6
BDP1 B double prime 1, subunit of RNA polymerase III transcription initiation factor IIIB +3.4
SMARCC1 SWI/SNF related, matrix associated, actin-dependent regulator of chromatin, subfamily c, member 1 +3.2
TRUB1 TruB pseudouridine (psi) synthase homolog 1 (E. coli) −4.4
HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 −3.9
SLC39A14 Solute carrier family 39 (zinc transporter), member 14 −3.6
NXT2 Nuclear transport factor-2-like export factor 2 −3.4
MALAT1 Metastasis-associated lung adenocarcinoma transcript 1 (nonprotein coding) −3.2
LARP5 La ribonucleoprotein domain family, member 5 −3.0
FGB Fibrinogen beta chain −2.8
ACTC1 Actin, alpha, cardiac muscle 1 −2.8
TFRC Transferrin receptor (p90, CD71) −2.8
RPS27A Ribosomal protein S27a −2.7
b
The top ten genes upregulated and downregulated the most by 5 μM Clofibrate (Table 1(a)), 0.1 μM AS601245 (Table 1(b)), and combined treatment
(Table 1(c)) with respect to DMSO-treated Caco-2 cells at 24 h.
is necessary for the growth of colorectal cancer in mice
[24, 25]. For these reasons, we analysed in colon cancer
cells the expression of STAT3 protein and the phosphory-
lation of STAT3 after clofibrate and AS601245 treatments
(Figures 7(a), 7(b), 7(c) and 7(d)). STAT 3 expression did
not vary after the treatments, and the amount of serine-
phosphorylated STAT3 did not vary either. Interestingly,
the amount of tyrosine-phosphorylated STAT3 is strongly
decreased after treatments with the highest concentration of
AS601245 and in particular after combined treatment, which
induced a synergistic decrease of phosphorylation.
3.6. Effects of AS601245 and Clofibrate in HepG2 Cells. Since
fibrates and other drugs are principally metabolized in
liver, we tested the toxic effect of 5 μM clofibrate, 0.1 μM
AS601245, and the association of the two substances in a
liver cell line: the HepG2 cells, which has been demonstrated
to be responsive to hepatotoxic compounds [26]. Acute
toxicity was evaluated with the MTT test, performed 2 hours
after the chemical additions. The amount of viable cells was
determined by using the trypan blue dye exclusion test also.
Results confirmed that 5 μM clofibrate, 0.1 μM AS601245,
and the combined treatment with the two substances did not
cause acute toxicity in HepG2 cells (data not shown). In this
cell line, the effect of clofibrate, AS601245, and combined
treatment in inhibiting cell proliferation was been evalu-
ated (Figure 8(a)). All treatments reduced cell proliferation
starting from 48 hours after the beginning of experiments,
and the inhibitory effect reached the maximum at 72 hours.
No significant differences were found between the three
different treatments. Since the reduction of proliferation can
be dependent on the modulation of specific gene expression,
we tested PCNA, cyclin D1, and p21 proliferation-related
protein expression, 24 hours after the treatments. PCNA and
cyclin D1 expression did not change after the treatments
(Figures 8(b) and 8(d)). On the contrary, p21 expression,
which did not change after the treatments in CaCo-2 cells,
was upregulated by clofibrate, AS601245, and combined
treatment in HepG2 cells (Figure 8(c)).
4. Discussion
Results obtained demonstrated that the combined treatment
with clofibrate and AS601245 inhibits proliferation and
downregulated the expression of two proliferation-related
proteins, PCNA and cyclin D1, 72 hours after the treatment
of CaCO-2 human colon cells. Caspase activities and TUNEL
test demonstrated that apoptosis increased significantly only
in cells treated with both compounds, whereas apoptosis
was not induced by such compounds, added separately. The
proapoptotic action of PPAR ligands has been reported in
many in vitro studies performed in some cancer cell lines
[27, 28]. However, at the concentration used in this study,
clofibrate alone did not induce a significant increase of
caspase activity in CaCo-2 cells. AS601245 was ineffective
too, although it modulated the expression of about 511 genes
belonging to the “cell death” group. On the other hand,
the JNK inhibition can elicit cellular responses, which range
from apoptosis induction to increased survival, depending
on the stimuli and the cell type [29]. Since the combined
treatment only was able to induce apoptosis, we paid
particular attention to genes, involved in the apoptotic
pathway, which were unaffected or slightly modulated after
the treatment with a single compound and highly modulated
by the combined treatment. Among the top ten genes
highly modulated by the combined treatment, the THRA
gene, which codifies for the thyroid hormone receptor, has
been shown to be related to the apoptosis induction of
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Table 2: Upregulated genes containing PPRE sequencesb.
Gene ID Gene name Fold change
Clofibrate None
AS601245
CYP1A1 Cytochrome P450, family 1, subfamily A, polypeptide 1 5.3
ITGB Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) 2.9
Clofibrate
+ 601245
AMFR Autocrine motility factor receptor 2.3
ANKRD12 Ankyrin repeat domain 11 2.2
CASP2 Caspase 2, apoptosis-related cysteine peptidase 2.7
CBX5 Chromobox homolog 5 (HP1 alpha homolog, Drosophila) 1.4
CCND1 Cyclin D1 1.9
CYP1A1 Cytochrome P450, family 1, subfamily A, polypeptide 1 7.5
DDX17 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17
DST Dystonin 1.8
DUSP6 Dual specificity phosphatase 6 2.2
EHBP1 EH domain-binding protein 1 2.4
EWSR1 Ewing sarcoma breakpoint region 1 1.8
FOSL1 FOS-like antigen 1 1.7
LMCD LIM and cysteine-rich domains 1 1.8
MARCKS MARCKS-like 1 2.5
MCAM Melanoma cell adhesion molecule 1.6
MLL3 Myeloid/lymphoid or mixed-lineage leukemia 3 2.7
NR2F2 Nuclear receptor subfamily 2, group F, member 2 2.4
PCYOX1 Prenylcysteine oxidase 1 1.3
RBM8A RNA-binding motif protein 8A 2.5
SPEN Spen homolog, transcriptional regulator (Drosophila) 2.2
TBL1XR1 Transducin (beta)-like 1 X-linked receptor 1 2.5
TTC3 Tetratricopeptide repeat domain 32 1.8
USP47 Ubiquitin specific peptidase 47 1.7
ZNF281 Zinc finger protein 281 1.5
ZNF294 Ring finger protein 160 1.9
b
The genes harbouring PPRE sequences among the upregulated genes by treatment with 5 μM clofibrate, 0.1 μM AS601245, and combined treatment versus
DMSO-treated Caco-2 cells at 24 h.
hematopoietic progenitor cells [30]. Several other genes,
up- or downregulated by the combined treatment only,
were involved in apoptosis induction. For example, CASP2
(caspase 2, +2.8-fold change) and KLF6 (Kruppel like factor
6, +1.5 fold change) [31, 32] were upregulated, whereas
ARHGEF7 (Rho guanine nucleotide exchange factor-GEF7)
[33] and RAB23 (member Ras oncogene family) were down
regulated by a 1.9- and 2.2-fold change, respectively (Table
A).
However, the most important change in gene expression,
after combined treatment regards the IL6ST gene, which
was induced about 6 fold, 24 hours after the treatment, as
demonstrated by affymetric analysis and confirmed by RT-
PCR. IL6ST (or gp130) is a universal signal transducing
receptor for all IL-6 family cytokines [34]. The role played
by IL-6 signalling in mediating tumour growth is equivo-
cal [35], in certain tumour cells, it inhibits proliferation,
whereas, in “in vivo” models, it stimulates cell growth.
Moreover, the significance of an increase of gp130 expression
also is controversial: on one hand, it may indicate an
increase in the response to the IL-6 family cytokine stimuli,
on the other hand, the soluble form signalling receptor
subunit gp130, which is generated by differential splicing,
is the natural inhibitor of IL-6 trans-signalling responses
[35]. We analyzed the downstream signalling of gp130,
through the analysis of STAT3 phosphorylation. STAT3 is
constitutively active in most tumor cells but not in normal
cells. Phosphorylation of STAT3 at tyrosine 705 leads to
its dimerization, nuclear translocation, DNA binding, and
gene transcription. The phosphorylation of STAT3 at serine
727 may regulate its activity negatively or positively [36].
AS601245 and, at higher level, the combined treatment
reduced STAT3 phosphorylation at tyrosine 705, indicating
a strong inhibition of STA3-induced gene transcription.
STAT3 regulates the expression of genes that mediate survival
and proliferation and can be involved in apoptosis induction
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Figure 6: PPRE binding activity and Western Blot analysis of Med1 and cyclin D1. (a) PPRE binding activity of PPARα. Results represent
the absorbance, detected at 450 nm, subtracted from the control value, and are the mean ± SD of three separate experiments from three
different preparations for each condition; (b) Western Blot analysis of Med1 protein detected in CaCo-2 cells treated with 5 μM and 50 μM
clofibrate (Clofi), 0.1 μM AS1245, and 5 μM clofibrate plus 0.1 μM AS601245 (Clofi + AS601245), collected at 24 hours after the treatment;
(c) Western Blot analysis of Med1 protein detected in CaCo-2 cells treated with 5 μM clofibrate, 0.1 μM AS1245, and 5 μM clofibrate plus
0.1 μM AS601245 (Clofi + AS), collected at 24, 48, and 72 hours after the treatment; (d) Western Blot analysis of cyclin D1 detected in CaCo-
2 cells treated with 5 μM and 50 μM clofibrate (Clofi), 0.1 μM AS1245, and 5 μM Clofibrate plus 0.1 μM AS601245 (Clofi + AS601245),
collected at 24 hours after the treatment. Graphics represent the relative quantification of protein products performed by densitometric
scanning. Data were normalized by using the β-actin signal, expressed as arbitrary densitometric units, and are the mean ± SD of three
separate experiments from three different preparations for each condition. Variance analysis: ∗P < 0.05, ∗∗P < 0.01 versus control.
and in reduction of cell proliferation caused by combined
treatment. Interestingly, AS601245 alone reduced in a dose-
dependent way STAT3 phosphorylation. This result is in
agreement with the work by Kim et al. [37] demonstrating
that a JNK inhibitor negatively correlated with the viability
of cancer cells and reduced STAT3 activity.
As far as it regards differentiation induction, clofibrate
alone did not increase differentiation of CaCo-2 cells.
AS601245 is more effective than clofibrate in inducing
differentiation, and it shows a synergistic effect when added
together with clofibrate. As well as for the apoptosis induc-
tion, the action of JNK in differentiation is controversial.
Ding and collaborators demonstrated that differentiation is
associated with increased JNK activity and c-Jun phosphory-
lation [38]. In agreement with these findings, inhibition of
JNK has been shown to attenuate intestinal cell differentia-
tion [39]. On the contrary, other authors demonstrated that
the MAP kinase pathway inhibitor U0126, in combination
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Figure 7:Analysis of JAK/STAT signalling.Western Blot analysis of STAT3 (a), P-STAT3 (Ser727) (b), and P-STAT3 (Tyr705) (c) proteins levels
analyzed in CaCo-2 cells treated with clofibrate (Clofi) alone, AS601245 alone at the indicated concentrations, and combined treatment with
5 μMclofibrate and 0,1 μMAS601245 (Clofi + AS) and collected at 24 hours after the treatment. Graphics represent the relative quantification
of protein products performed by densitometric scanning. Data were normalized by using the β-actin signal and expressed as arbitrary
densitometric units. (d) Graphics represent the normalization of the protein level of P-STAT3 (Tyr705) by using STAT3 signal. Results are
the mean ± SD of three separate experiments from three different preparations for each condition. Variance analysis: ∗P < 0.05, ∗∗P < 0.01
versus control.
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Figure 8: Effect of clofibrate and AS601245 in HepG-2 human liver cells. (a) Growth of HepG-2 cells treated with 5 μM clofibrate, 0,1 μM
AS601245, and the association of these two compounds (Clofi + AS601245); (b) Western Blot analysis of PCNA detected in CaCo-2 cells
treated with 5 μM clofibrate, 0.1 μM AS1245, and 5 μM clofibrate plus 0.1 μM AS601245 (Clofi + AS601245), collected at 24 hours after the
treatment; (c) Western Blot analysis of p21, detected in CaCo-2 cells treated with 5 μM clofibrate, 0.1 μM AS1245, and 5 μM clofibrate plus
0.1 μMAS601245 (Clofi+AS601245), collected at 24 hours after the treatment; (d)Western Blot analysis of cyclin D1 detected in CaCo-2 cells
treated with 5 μM clofibrate, 0.1 μM AS1245, and 5 μM clofibrate plus 0.1 μM AS601245 (Clofi + AS601245), collected at 24 hours after the
treatment. Graphics represent the relative quantification of protein products performed by densitometric scanning. Data were normalized
by using the β-actin signal, expressed as arbitrary densitometric units, and are the mean ± SD of three separate experiments from three
different preparations for each condition. Variance analysis: ∗P < 0.05, ∗∗P < 0.01 versus control.
with butyrate, promotes differentiation in some colon cancer
cell lines [40]. Our results demonstrated that AS601245, at 24
hours, did not increase the number of Domes, whereas, after
48 hours, differentiation induction was evident. Moreover,
the addition of AS601245 to clofibrate increased the differ-
entiation of CaCo-2 cells both at 24 and 48 hours.
By analysing the expression profile of the genes involved
in this pathway, we found some genes affected by AS601245,
which were further modulated by the association of these
two compounds (Table A). A role, in the differentiation-
process, may be played by the MGA gene, activated by 2.361-
fold in AS601245-treated cells and by 3.089-fold in cells
treated with AS601245 and clofibrate. This gene codifies a
member of MAD family proteins belonging to the Max/Mad
network which is involved in the control of various aspects
of cell behaviour, including proliferation, differentiation, and
apoptosis [41].
Clofibrate alone, at the concentration of 5 μM, did not
activate genes containing PPRE sequences, probably because
of its low concentration. However, when added together with
AS601245, 28 genes containing putative PPRE sequences
were upregulated. This datum is in agreement with the
hypothesis of an increase of PPAR transcriptional activ-
ity after JNK inhibition [42] and is further sustained
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by the results obtained in PPRE binding activity, which
demonstrated a strong increase in DNA binding of cells
treated with both AS601245 and clofibrate. The gene
expression profile revealed that the expression of the
PPARα activator MED1 was increased by 1.8-fold in cells
treated with both compounds only. MED1 (also referred as
PBP/TRAP220/DRIP205) was shown as a critical component
of the TRAP/DRIP/ARC/Mediator complex [43] which
facilitates interaction of ligand-activated PPAR with RNA
polymerase and the general basal transcription machinery
to enhance the transcription of a specific set of genes [44–
46]. Western Blot analysis confirmed the increase of MED1
protein in cells treated with 5 μM clofibrate plus 0.1 μM
AS691245. This increase remained elevated in the cells
treated with both compounds until 72 hours after the treat-
ment. Moreover, an increase of MED1 expression occurred
even in 50 μMclofibrate-treated cells. These results paralleled
with the increase of PPRE binding activity and may suggest
thatMED1 expression was involved in increasing the number
of genes, containing PPRE sequences, activated by combined
treatment. According to this hypothesis, we demonstrated
that the expression of cyclin D1 protein, codified by a
gene containing PPRE sequences that was upregulated after
combined treatment, was increased, not only after combined
treatment, but also after treatment with 50 μM clofibrate.
The experiments performed in HepG2 cells showed
that the single and combined treatment did not induce
hepatotoxicity in human liver cells. Moreover, the analysis of
the effect of these compounds on HepG2 cells proliferation
indicated that there was no synergistic effect between
clofibrate and AS601245. In this cell line, the pattern of
proliferation-related protein expression was different from
that detected in CaCO-2 cells. Indeed, in HepG-2 cells, the
p21 expression was increased in clofibrate, AS601245 and
clofibrate plus AS601245, treated cells. This result may be
related to the fact that HepG2 cells have a wild-type p53 gene
[47], whereas, in CaCo-2 cells, p53 is not expressed [48].
5. Conclusions
Taken together, our data demonstrate the effectiveness of
combined treatments with PPARα agonists and a JNK
inhibitor in inducing apoptosis, differentiation, and PPRE
binding activity in colon cancer cells and support the data
suggesting a positive interaction between PPARα ligands and
anti-inflammatory agents in humans [49, 50]. The positive
interaction originates from the modulation of several sig-
nalling pathways which were affected by the association of
clofibrate and AS601245.
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